Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
November 5, 2020
Earnings Call Speaker Segments
Holly Manning
executiveOperator, thank you. Greetings, everyone, and thanks for joining us for Agios's Third Quarter 2020 Conference Call. Today's presentation slides are available in the Investors section on agios.com, our website. With me today to deliver prepared remarks are our Chief Executive Officer, Dr. Jackie Fouse; our Chief Medical Officer, Dr. Chris Bowden; Darrin Miles, who serves as Senior Vice President of U.S. Commercial and Global Marketing; and Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs. Our Chief Scientific Officer, Dr. Bruce Car, will join us for the Q&A portion. Before we get started, please be aware that some of what we say during this call will consist of forward-looking statements. A range of risks, unknowns, and other considerations—among them the items listed under Risk Factors in the latest Form 10-Q we submitted to the SEC, along with any subsequent documents we file with that agency—could cause real outcomes and developments to vary substantially from anything suggested or stated in forward-looking remarks. Having said that, I'll now hand things over to Jackie.
Jacqualyn Fouse
executiveAppreciate it, Holly. Morning, everybody, and thank you for being on the call about our results for the third quarter of 2020. What we concentrated on during this quarter was carrying out the main things we set as priorities for 2020, doing substantial planning and getting ready for a fourth quarter full of catalysts along with 2021, and a firm dedication to acting in the best interest of patients and our employees while we keep dealing with the continuing consequences of the COVID-19 pandemic; we achieved meaningful progress in delivering our medicines to the patients who require them. That covers producing mature overall survival data from ClarIDHy, which makes possible our first regulatory filing in solid tumors, and starting our healthy volunteer study for AG-946, our PKR activator of the next generation. Away from public view, we have been working diligently to get ready for major milestones arriving later in 2020 and across 2021, such as top line data readouts from ACTIVATE and ACTIVATE-T, the supplemental NDA submission for TIBSOVO in cholangiocarcinoma, and kicking off our global pivotal studies of mitapivat in thalassemia and sickle cell disease. To assist in steering us toward these crucial value inflection points, we named Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs in September. Jonathan has been a colleague of mine for a long time, and his expertise has been a welcome addition to our leadership team since he came aboard in November of last year. You will hear from him afterward on this call when we go over our quarterly financials; we also had to handle certain challenges, among them the requirement to pull our marketing authorization application for TIBSOVO in the relapsed/refractory AML setting in the EU. Our continuing Phase III combination studies of TIBSOVO in the frontline AML setting stay on schedule for those considerably larger patient populations. Withdrawing our MAA will not bring about any near-term adjustments to how we operate in the region. Our small EU team concentrates mostly on backing Agios' clinical trial and medical affairs work and PKD market development efforts, which include patient advocacy, disease education and patient identification. Spending in the EU will stay gated and matched to when future product approvals occur in the region. Turning to what's left of the year, we have several key events for our mitapivat program that will further clarify the potential value of the PKR activation mechanism for treating serious hemolytic anemias. To begin, on November 19, we will host an investor webinar centered on our PKR franchise, which will feature a deep dive into the mechanism of action; the unmet patient needs in thalassemia, sickle cell disease and PK deficiency; how we see these market opportunities and the commercial preparations currently in progress for our first potential rare disease launch. Alongside ASH, we're going to hold an investor event on December 8, where we'll present updated data from the NIH Phase I trial of mitapivat in sickle cell disease, plus a look at our Phase III plans in thalassemia. And lastly, because of the incredible work our team has put in, we now anticipate top line data from the ACTIVATE study of mitapivat in nontransfusion-dependent PK deficiency before the year is out. The next few months are going to be full, and I'd like to express my gratitude to every single Agios employee for pushing our programs forward for patients even as the pandemic keeps affecting their lives both personally and professionally. Chris, I'll hand things over to you now.
Chris Bowden
executiveThank you, Jackie. I want to begin by discussing mitapivat, which is our first-in-class PKR activator and is presently under evaluation in 3 separate hemolytic anemias. As Jackie pointed out, we expect a number of significant milestones over the next several weeks, and those will move forward all 3 of our mitapivat programs. Let me begin with the program that is furthest along, in pyruvate kinase deficiency, where 2 Phase III clinical trials are underway and where we could potentially deliver the first disease-modifying therapy for this condition. Earlier in the year, we provided guidance pointing to top line data from the ACTIVATE and ACTIVATE-T studies at some point between the close of this year and mid-2021, with expectations of some delays stemming from the pandemic. Owing in large part to the remarkable dedication of our Agios team, we can now tighten those timelines. For ACTIVATE, the randomized, placebo-controlled Phase III study involving 80 adults who have pyruvate kinase deficiency and are not regularly transfused, we expect top line data by the end of 2020. For ACTIVATE-T, the Phase III single-arm open-label study involving 27 adults who have PK deficiency and are regularly transfused, we expect top line data during the first quarter of 2021, because follow-up in this study takes longer. Should the results be positive, we plan to seek regulatory approval for a broad label covering adults with PK deficiency in both the U.S. and EU next year, with a possible commercial launch in 2022 across both regions. Now I'll move to the Phase II study of mitapivat in thalassemia. Enrollment was completed earlier this year, with 20 patients. And in June, at the virtual EHA meeting, we presented updated data covering 13 efficacy evaluable patients. Those data demonstrated that mitapivat treatment produced a hemoglobin increase of greater than or equal to 1 gram per deciliter in 12 of 13 evaluable patients during weeks 4 through 12, including 4 out of 4 alpha thalassemia patients, a group for whom no new treatment options have emerged in decades. Additionally, 7 of 8 beta thalassemia patients reached a sustained hemoglobin response during weeks 12 through 24. We plan to submit the complete data set from this study for presentation at a medical meeting in 2021; during this quarter, we have been working through feedback from U.S. and EU regulators on our pivotal program. At our ASH event in December, we expect to share specifics of our robust pivotal development plan, which covers both alpha and beta thalassemia along with transfusion-dependent and nontransfusion-dependent patient populations; we anticipate launching our pivotal program in 2021. Let's now move to sickle cell disease, where our collaboration is with Dr. Swee Lay Thien of the National Institutes of Health on a proof-of-concept study involving mitapivat. In June, we announced that clinical proof-of-concept had been established, based on a preliminary analysis of data from 8 patients. Those data showed that across a 6- to 8-week dosing period, 7 of 8 patients had a hemoglobin increase, and 5 of 8 patients achieved a hemoglobin increase of greater than or equal to 1 gram per deciliter from baseline. Recruitment for the trial was halted for a period extending into the spring because of the COVID-19 pandemic, and it started again as of the middle of August. Right now, 13 patients have been signed up for the study. During ASH, Dr. Thien is going to deliver an oral presentation featuring refreshed data covering no fewer than 11 patients — the 8 individuals from the preliminary analysis plus roughly 3 more who are anticipated to finish the study in time for inclusion in the presentation. Altogether, 5 patients — 2 from the top line preliminary and all 3 of those newly enrolled — were given the 100-milligram BID dose and are going to be part of the ASH presentation. Information gathered from the trial once it is fully enrolled is going to be submitted for presentation at a medical meeting next year. Looking ahead, the NIH approved a new protocol not long ago, which permits every patient in the Phase I study to keep getting mitapivat during an extension phase lasting as long as 2 years. That extension is going to yield valuable long-term safety and efficacy data in sickle cell disease, a condition where patients may potentially remain on therapy for many years, perhaps for life. Alongside these clinical activities, we are moving quickly to secure U.S. and EU regulatory feedback so we can push forward our sickle cell disease pivotal development plan. We anticipate sharing an overview of how the pivotal program is designed during the first half of 2021 and launching the study within the year. Now I'll turn to our malignant hematology programs. Last month, we disclosed our decision to withdraw our marketing authorization application for TIBSOVO in relapsed/refractory AML following the feedback we received at the oral explanation in September. Even with what we learned from the IDHIFA experience and the further in-depth efforts by our team, we could not fully resolve the major objections the CHMP raised in order to back a positive benefit/risk assessment in the proposed indication based on a single-arm, noncomparative Phase I/II study. Although it disappoints us that patients in the EU won't be able to access TIBSOVO in the near term, we are still enrolling the AGILE and HOVON Phase III combination trials in IC-eligible and IC-ineligible frontline AML. Should those trials prove positive, we expect to seek approvals in the U.S. and the EU. The overwhelming majority of patients newly diagnosed with AML qualify to receive intensive or nonintensive therapy. Thus these studies give us the chance to reach the greatest number of patients. Turning to our solid tumor programs. Last year, we reported positive, highly statistically significant progression-free survival data from the ClarIDHy Phase III study of TIBSOVO in previously treated IDH1 mutant cholangiocarcinoma. And last month, we provided a top line look at mature overall survival, a secondary end point in the study. Treatment with TIBSOVO was linked to a nonstatistically significant improvement in overall survival relative to placebo. Since 70% of patients in the placebo group switched over to the ivosidenib group, we view this favorable overall survival trend as meaningful supporting evidence for approval; we're going to share these findings with FDA and intend to file a supplemental new drug application for TIBSOVO in previously treated IDH1 mutant cholangiocarcinoma during the first quarter of 2021. Also, we've submitted the ClarIDHy final overall survival data set for possible presentation at ASCO-GI in January. The strong and statistically robust PFS results backed adding TIBSOVO to the NCCN treatment guidelines at a level recommendation equal to approved therapies for other biomarker-selected populations; this degree of endorsement from expert physicians is an encouraging acknowledgment of TIBSOVO's clinical benefit. Beyond cholangiocarcinoma, we're investigating IDH inhibition's usefulness in low-grade glioma through our Phase III INDIGO trial of vorasidenib. Vorasidenib is our brain-penetrant, dual IDH1 and 2 inhibitor that could potentially treat the roughly 80% of low-grade glioma patients who have an IDH mutation. Site start-up activities are running ahead of expectations even with the pandemic, which reflects physician enthusiasm for vorasidenib's potential and for this trial. And lastly, the AG-270 Phase I dose-escalation combination arms with taxanes are still enrolling patients. With that, I'll hand things over to Darrin to talk about our third quarter commercial performance.
Darrin Miles
executiveAppreciate that, Chris. The momentum from the first half of 2020 carried right on into the third quarter, which gave us $32 million in net sales for TIBSOVO — that's a 15% rise versus Q2. What drove the quarter was a big jump in new scripts and refills, plus ongoing gains in duration, now at roughly 5 months. We're still seeing growth in the academic setting and the community setting alike, but the pickup in community use stood out as especially robust, and that mirrors the pattern of more co-management of patients between academic and community physicians, which the COVID-19 pandemic probably sped up; steady gains continue in physician preference share for TIBSOVO in the frontline intensive chemo ineligible and first relapse settings. Every leading indicator of how physicians perceive TIBSOVO looks favorable, among them a notable rise in the share of physicians who consider TIBSOVO the standard of care for newly diagnosed intensive chemo-ineligible patients. Our promotional activity stays confined to the on-label AML opportunity, yet we did see commercial volume grow on the cholangiocarcinoma side after TIBSOVO was added to the NCCN guidelines in June. Visibility into indication-specific use is limited to the specialty pharmacy channel, which accounts for roughly 1/3 of TIBSOVO commercial volume, so the uptick in cholangiocarcinoma utilization after the practice guidelines update was worth flagging. Some geographies have loosened up a bit, but in-person customer interaction, especially with academic customers, is still mostly restricted, and we expect those restrictions to tighten once more as we move into the late fall and winter months. Even so, our team has done well leveraging virtual communication and educational tools to keep live customer engagement going. That let us grow our count of new customers by 17%. The fourth quarter outlook is solid, though not free of possible headwinds. Leading indicators and early Q4 performance point to trends much like Q3. That said, we also expect disruption in how many AML patients get diagnosed and possibly treated, since COVID-19 infections and hospitalizations are projected to climb through year-end; on top of that, we could see more volume flowing through Medicaid and 340B channels because of the pandemic, which can put added pressure on gross to net. Taking into account our year-to-date results and what we expect for the rest of the year, we are narrowing 2020 net U.S. TIBSOVO sales guidance from between $105 million to $115 million down to $113 million to $115 million. I'd like to thank the Agios team for not merely adapting but thriving amid these uncertain times, driven by a passion to make sure no patient is denied the chance to benefit from our treatments. I'll hand things over now to Jonathan for our third quarter financials.
Jonathan Biller
executiveThanks, Darrin. You can find our third quarter results in this morning's press release, and I'll walk through them. Additional detail will come in our 10-Q filing later today. Revenue for the second quarter totaled $35 million, made up of $32 million in net sales of TIBSOVO, $2 million in collaboration revenue, and $700,000 in royalty revenue. Versus the third quarter of 2019, total revenue increased 33%, powered by an 82% rise in TIBSOVO sales, partly offset by lower collaboration revenue following completion of the research and development service obligation with Celgene in Q2. Also, royalty revenue took a hit from a sales reserves adjustment BMS recorded this quarter tied to prior periods. TIBSOVO revenue climbed by $4 million versus Q2 2020 on stronger demand. Gross to net for the quarter landed within the expected range. We keep watching Medicaid and PHS utilization. Cost of sales for the quarter came to $637,000. Now to operating expenses. R&D for the third quarter reached $90 million, down $12 million from the third quarter of 2019. That year-over-year drop in R&D stemmed largely from lower TIBSOVO clinical development costs, including winding down the ClarIDHy Phase III study. Selling, general and administrative expenses totaled $35 million for the quarter, a $2 million increase over third quarter 2019, mainly from higher workforce expenses, partly offset by lower external spending due to COVID-19 and cost savings initiatives. We closed the quarter with cash, cash equivalents and marketable securities of $722 million. We expect our Q3 ending cash balance, plus anticipated product revenue but excluding expected program-specific milestone payments, to fund our current operating plan through the end of 2022. With that, operator, please open the line for questions.
Anupam Rama
analystLet me ask something brief regarding AG-946. What's the right way to frame the expected timing for the healthy volunteer results? I realize the study has only just begun, but what matters here is the launch of that SCD cohort you're running for 946, and how that fits with the schedule for the mitapivat Phase III that you described a year ago.
Chris Bowden
executiveAnupam, this is Chris Bowden speaking; the 946 trial is currently underway in healthy volunteers. As with what we did for mitapivat in healthy volunteers, these are single dose cohorts, after which we progress to the multi-ascending dose cohorts. Once that's done, we intend to launch a sickle cell cohort. So at this point it's premature for us to say when we expect to move into that stage, or when we expect to be able to publish data. As before, whenever we believe we've accumulated a critical mass of safety, PK, and PD data, we'd aim to get that released, and possibly near that point we could indicate when the sickle cell cohort is likely to open; as for kicking off our Phase III with mitapivat and sickle cell, that happens next year. Thus we're — as I mentioned in my remarks, we're fully engaged in developing a protocol and in discussions with the health authorities, and we'll have more to share on that next year too.
Tyler Van Buren
analystI want to ask about the mitapivat sickle cell update that came out at ASH. Specifically, how much confidence do you have that the 100-milligram BID dose is going to deliver a clinical benefit that's more meaningful than what we see with 50-milligram BID — especially regarding hemoglobin? The abstract showed hemoglobin rising by 0.9, compared with 1.2 on the 50 mg. Of course, there were only 2 patients on the 100 mg, versus 8 on all the other doses. So it's possible those 2 patients had something distinctive about them. But I'd like to hear how you explain that, and again, how confident you are that the 100-milligram dose will show better benefits.
Chris Bowden
executiveYes. What I'd emphasize is that the figures you're seeing are changes measured against baseline. And keep in mind how the trial was set up: participants continue titrating upward. They start at 5, and then they're able to reach 50, or after the amendment was introduced, they could go as high as 100; that covers each of those 8 patients, regardless of whether they had a response. So in my view, attempting to distinguish the 50 versus 100 results by looking at the table is somewhat difficult. Think back to the high-level points we covered in our opening comments at EHA: five out of eight patients saw hemoglobin rise by at least one gram, and every one of them was on 50. That tells us 50 milligrams is clearly an active dose. Based on our healthy volunteer data and other findings, we'd likely observe a greater quantitative response as we move from 50 up to 100. It differs case by case. And perhaps the key takeaway here is that patients may ultimately be able to receive a range of doses. We haven't yet settled on whether it should be 50, 100, or both 50 and 100. Consider it this way: suppose you saw a rise of 1.5 grams at the 50 level, plus an additional gain of 0.7 grams, or maybe 0.5 grams, once the dose moved up to 100. With the kind of findings now surfacing regarding hemoglobin and patient outcomes, that sort of effect would plausibly count as a clinical advantage—something doctors and patients would care about—provided the safety picture held up as similar, and from 50 through 100 it does appear comparable. The information coming out of this trial, along with what we've gathered from several other studies, has genuinely boosted our confidence regarding the dose we're picking and how we put a trial together. More specifics on that should be available during the first half of 2021.
Tyler Van Buren
analystAlright. Perhaps a single follow-up question; you brought up 11 patients who will have data presented at ASH, with 8 receiving the 100 mg BID dose, and 3 of those are new while 5 come from the group already enrolled, meaning they've had their dose escalated. Do all of them get their dose raised to 100 milligrams BID within the same period or during the same cycle? And if that isn't the case, does it have any bearing on hemoglobin response?
Chris Bowden
executiveI believe — assuming I've got your question right, what happens is you're on the drug for 2 — the dose stays at 5 milligrams for 2 weeks, then 20 milligrams for 2 weeks, then 50 milligrams for 2 weeks, and after that 100 milligrams for 2 weeks; so no interruption occurs at any point. Enrollment of patients happens one after another; thus it isn't the situation where the entire cohort arrives and all are enrolled simultaneously, yet dosing frequency remains comparable across every patient.
Marc Frahm
analystChris, I wanted to pick up on something you said earlier, only about a minute back, regarding 100 milligrams compared with observing some benefit at 50. For the long-term extension, will that be at 100 milligrams? Or does it involve some form of individualized dosing depending on what each patient prefers? Also, a lot of these patients rolled off trial back in the spring, correct; so must they dose-escalate again? Or do you believe they can simply be put straight back onto the drug?
Chris Bowden
executiveWhat will happen is they get them to what is — what they consider an optimum dose within that 50 to 100 milligram range, and they are just going to come in at 50.
Marc Frahm
analystUnderstood. So regarding those already on treatment, the expectation is that the more recent patients are simply going to begin transitioning directly into that study?
Chris Bowden
executiveThey'll simply be in a position to shift over into the extension. That is right.
Marc Frahm
analystAlright, alright. And for testing that entire process — the step-down and titration out you've been carrying out — would another washout period be part of it? Or do you figure your existing experience suffices?
Chris Bowden
executiveYes. So the taper — since it's a distinct protocol, they will have to complete it, then re-enter. That's the reason. I don't — we don't — I don't believe extra data on the taper is needed past what's already arranged in the study that's running at present.
Marc Frahm
analystAll right, that's helpful. Then I just want to touch on one item regarding the abstract; it mentions a potential second way the drug works involving Gardos. Could you walk us through what leads you to that conclusion? And after that, perhaps you could compare it with prior Gardos research in sickle cell, since clearly a prominent Phase III study has been conducted in that area previously.
Chris Bowden
executiveSure. This topic has drawn attention from our research group as a possible mechanism, and more recently from the investigators, prompted by the rise in mean corpuscular volume, known as MCV. Since you're boosting overall red blood cell health, and possibly affecting the Gardos channel, which plays a direct role in red cell hydration, that might be another route through which mitapivat delivers clinical benefit. The cells survive longer. They are in better condition, with improved hydration status, which could reduce or lessen polymerization of that fiber.
Marc Frahm
analystAll right. And I suppose, is there anything that separates the way you figure this is operating from whatever was examined previously involving Gardos? Since my understanding is that Phase III study, well, it clearly didn't succeed when it came to VOCs, but in terms of achieving stat sig, it even revealed a trend that went against the drug, correct?
Chris Bowden
executiveRight. That trial was quite fascinating, since that Gardos channel blocker produced a certain amount of hemoglobin improvement, yet it was halted over a concern related to VOCs and safety. The way we operate is quite distinct. We don't act on the Gardos channel in a direct manner. What our drug does specifically is activate pyruvate kinase, and as we keep stressing, it's the effect upon the glycolytic pathway from activating PKR that raises ATP, and there you observe multiple favorable outcomes regarding red cell health, and subsequently, through lowering 2,3-DPG, which has long been shown to be higher in sickle cell patients. You — the basis for confidence is that this will reduce the creation of fibers responsible for that aberrant red cell shape along with sickling and every one of the negative consequences that follow. So it's quite — it's a finding that perhaps we're enhancing the capacity of that Gardos channel to bring about greater red cell hydration, yet it happens essentially via that mechanism of action, which is boosting ATP through activating PKR.
Peter Lawson
analystThis is Waleed filling in for Peter. My question concerns the PKD data coming up — where do you view the bar, and what counts as clinically meaningful when we get data at year-end and in Q1 '21, for both transfusion-independent and transfusion-dependent patients?
Chris Bowden
executiveChris Bowden here. Yes. Both of those trials were designed with an end point that will be tied to clinical benefit. And naturally, we'll examine secondary end points very closely. In the ACTIVATE study, a responder means a hemoglobin rise of 1.5 grams or more from baseline. That trial has 80 patients, randomized one-to-one to active drug or placebo, with placebo patients able to cross over once the dosing period ends. We'd have a positive study if the response rate is 35%, assuming roughly 5% response in the control arm. That would make it positive. Based on DRIVE PK, where over 1 gram is what clinicians point to when discussing clinical benefit, we set the bar higher still; so if the primary end point is met, we have considerable confidence the package indicates clinical benefit. A number of supporting secondary end points will matter too in that not regularly transfused population. For ACTIVATE-T, which enrolls 27 patients who are regularly transfused, the efficacy end point is a reduction of 33% or more in overall transfusion burden while in the study, versus their prior 1-year transfusion history. That's an open-label trial; the primary measure of clinical benefit is what I just described. Meanwhile, in regularly transfused patients, people also look at 50% — a 50% reduction — and transfusion independence. Those are the other key secondary efficacy outcomes that we hope will show mitapivat has a really big impact for that group by cutting the time they must spend in the clinic receiving blood transfusions. We'll also assess secondary end points such as iron mobilization and any effects on the need for iron chelation, among others. So with the 2 trials together, we'd like to use them to secure a broad label in adults with pyruvate kinase deficiency. And we believe the trials as a package are set up to truly demonstrate clinical benefit overall.
Mohit Bansal
analystThanks. Before anything else, Jonathan, congratulations on stepping into your new position. Let me get into my question. I believe when that $1 billion target for 2025 was initially put out there, clearly, COVID hadn't happened yet, and more recently there was an EMA ruling that went against you. So might you elaborate a bit further on, given all this uncertainty, how realistic that $1 billion by '25 target is, or aspiration, and how much flexibility exists through the pipeline and so forth to still deliver it should the current — today's business not perform as expected?
Jacqualyn Fouse
executiveMohit, this is Jackie. I appreciate the question. I figured I wouldn't get a chance to speak during the Q&A today, so I'm glad for the opportunity. As you can probably guess, we aim to set ambitious goals, yet goals we believe carry a very high likelihood of being reached. Regarding that $1 billion, our revenue guidance, it's largely fueled by TIBSOVO and AML, specifically the indication tied to label expansions. That said, we also have some revenue baked in for mitapivat in PKD, where I personally believe we've been somewhat conservative. And then there's where we've included almost nothing at all — for vorasidenib in glioma and for mitapivat in thalassemia and sickle cell disease — since, from a time line perspective, our base case assumption places them fairly late within the time horizon, but even slightly pulling those forward, or a somewhat quicker revenue ramp at launch than you've modeled, would leave you ample room to still hit the objectives. What we've actually observed too, as you can see in 2020 with TIBSOVO revenues, is that oral oncolytics during the pandemic setting might in fact be advantaged. So we've been quite pleased with how TIBSOVO has performed in 2020 thus far. We haven't issued guidance for 2021 yet, though we'll do so shortly, and then — at the start of next year; and we feel pretty good about our position with TIBSOVO in that — the base case in AML. So your point about the pandemic and COVID affecting the $1 billion in 2025 — honestly, we haven't yet seen that become a problem. As a matter of fact, we might be somewhat ahead of what we'd originally anticipated. So I feel wonderful about it. And I believe my statements have consistently been at least $1 billion in 2025, and that remains how I feel.
Mohit Bansal
analystUnderstood. If I could squeeze in one more for Darrin. Thanks for that, Jackie; I realize you'll be covering a great deal of this on November 19, but could I get an early look, since whenever we discuss PKD with physicians, they frequently claim the patient pool is tiny and they don't encounter many such individuals. So given that, where do you currently stand when it comes to locating PKD patients? And is — does some easy opportunity exist there? Or what's — what approach would you take to track down these patients and likely grow the market?
Darrin Miles
executiveWonderful. Appreciate the question. So I believe we've stated publicly, correct, that — in the past that our estimate for the PKD population sits at somewhere between 3,000 to 8,000, correct, spanning the U.S. and 5 EU, correct, possibly reaching 10,000 once you factor in the entire EU. The patient identification work we've carried out across the past couple of years has produced roughly 1,000-or-so patients divided across the U.S. and the 5 EU, plus a number of extra patients found outside those major markets too; so factoring all of that in, roughly 1/3 of the — what we've found as of today, correct, approximately 1/3 — slightly over 1/3 of the bottom end of the possible prevalence — prevalent population. Yet much of what the effort involves — or keeps involving through to approval for mitapivat, correct? So simply intensifying that patient identification effort alongside disease education, disease awareness, advocacy and similar things. And that effort continues in both the EU and the U.S.
Bikramjot Singh
analystThis is Bikram, filling in for Kennen. I've got one quick question about the EU regulatory feedback you received. Could you maybe walk us back through what the regulatory agency's primary issues were there — the ones that resulted in the withdrawal — and also your level of confidence in the Phase III studies alone, plus any timeline updates for HOVON and AGILE? Since getting that feedback, has your thinking or confidence shifted at all? That would be really helpful.
Chris Bowden
executiveYes. Chris Bowden speaking here. Our excitement and confidence regarding the Phase III trials, conducted in newly diagnosed patients, matter a great deal, since — as I mentioned during my remarks — that is where you find the largest number of patients. So we remain deeply committed to those studies. They are underway. COVID's impact forced us to reset our guidance for AGILE, and our goal is to complete accrual in the AGILE study by the close of next year. As for the HOVON study — that one covers IC-eligible patients, and we haven't provided guidance on it yet. It sits in its operational — early operational stage, with sites joining. Still, we are clearly observing solid accrual for both IDH1 and IDH2. This is being run within a group dedicated to conducting — an international group dedicated to conducting research in this IC-eligible patient population. They possess a lengthy history of doing exactly that. So we feel genuinely pleased with the progress there, and they are excellent partners. Now, regarding the MAA. There was certainly, in my view, recognition that we demonstrated clinical activity using TIBSOVO in the relapsed/refractory setting, that the oral agent and those durable responses drew appreciation. Our primary issue — and we anticipated this going in — was the absence of a control arm. So here — the CHMP has historically reviewed these kinds of data sets. Considerable skepticism exists. We put substantial effort into examining historical control data, part of which will be published at ASH, showing what appeared there — what showed remarkably strong effects on survival relative to an IDH1 historical control among relapsed/refractory disease patients. Ultimately, that simply did not suffice; and absent controlled clinical data in the relapsed/refractory setting, the CHMP would not issue a positive opinion, which we understood following our oral explanation, and that is when we chose to withdraw.
Jacqualyn Fouse
executiveRight, so this is Jackie hopping in briefly. Any time you move forward with a Phase I data set like this, with no control arm in Europe, there's a chance you land in this kind of spot. We believed giving this a try was the right call for patients. We gave it a really strong try. As Chris mentioned, you'll see some data come out regarding the historical control work we did, and I think that remains quite interesting data. But our base case assumptions did incorporate certain assumptions about this risk. And like Chris said, within the relapsed/refractory IDH1 patient population, it's a fairly modest size in Europe, with pricing assumptions that differ from those in the U.S. So it was a modest revenue opportunity, and we're pressing ahead at full speed with the Phase III trials, which are the sort of trials you'd expect the Europeans to want to see for label expansions in the newly diagnosed, so it's simply a different situation with AGILE and HOVON.
Bikramjot Singh
analystRight. I also wanted to ask a quick follow-up regarding TIBSOVO, specifically around U.S. revenue trends. You brought up the gross-to-net effect that could be coming in Q4, plus diagnosis rates. During Q3, was a low diagnosis rate something you were also observing? Q3 growth was quite robust, as was demand growth, from what I understand. So perhaps you could discuss some of the dynamics and what you anticipate for Q4, considering the rise in cases across the U.S. — COVID cases.
Darrin Miles
executiveRight. Of course. So the — what I attempted to lay out were certain possible headwinds that remain mostly unknown, correct? We recognize that a resurgence is happening and will keep happening. From what we learned during the first surge, it definitely affected patients — their presentation, whether they got diagnosed, and diagnosis overall — although we handled it fairly well, especially given that this is an oral therapy for something like AML, a disease where urgency is high, correct? The — Q3 presented a very different situation, correct? So there were — despite hotspots appearing throughout the U.S., the experience wasn't quite what we're beginning to face in Q4. Therefore, what I wanted to make sure of is that we strike a balance between excitement about the Q3 results and the possible, genuinely possible, COVID-related effects in Q4. That being said, gross-to-net effects mostly stem from a possible shift in the coverage mix for patients taking commercial drug. A major shift hasn't appeared, but it could happen, given economic conditions and how they affect jobs and therefore insurance coverage — maybe more Medicaid coverage, along with patients going through 340B or DSH hospitals. Those are the — that's what we're expecting throughout this — throughout Q4, which might create some headwinds for our overall performance.
Jacqualyn Fouse
executiveAdditionally, I believe Darrin mentioned during his prepared remarks that, despite all those caveats, October got us off to a really strong beginning for Q4.
Darrin Miles
executiveYes. We're pretty pleased with what we've seen so far in the quarter.
Emma Nealon
analystThis is Emma, sitting in for Alethia. Coming back to sickle cell — we noticed a different PKR activator currently being developed laid out a pivotal study in their ASH abstracts, and that study had annualized VOC as one of its co-primary end points. I realize you're still talking with regulators about the planned mitapivat design, but do you view that as something important to demonstrate differentiation on, so you can compete against that agent, or against commercial drugs such as Oxbryta?
Chris Bowden
executiveOkay, so — this is Chris speaking. My view is that any — if a trial is going to be conducted using a PKR activator, then as we've stated right from the start, there are 2 reasons to believe, and one of them is hemoglobin going up while the other is VOCs coming down. That means there are many possible ways to structure the trial — could be co-primary end points, could be sequential testing. So it should go without saying that those 2 end points are the marquees; that's where patients get clinical benefit; and I'd say the big promise, the potential, so to speak, for mitapivat is being able to significantly hit both. Clearly, there are drugs we're seeing approved for raising hemoglobin while the jury is still out regarding what happens with VOC reduction, and our hope is that with longer follow-up, you might observe a decrease in — a statistically significant decrease in VOC with voxelotor. That would benefit patients. The P-selectin inhibitor from Novartis brings VOCs down, but it doesn't really — it has no impact on hemoglobin. What we hope for, the potential and the promise for mitapivat, is that both can be addressed and that you'll be able to address the 2 main problems of sickle cell disease and PKR activity.
Emma Nealon
analystGreat. Is there anything new you can share regarding the pediatric development plan across the PKR portfolio, for both mitapivat and 946?
Chris Bowden
executiveOur pediatric program with mitapivat is progressing in patients who have pyruvate kinase deficiency, and we are working to get those studies started. When it comes to thalassemia and sickle cell, for mitapivat, those definitely will need to be done. But at this moment we're concentrating on pyruvate kinase deficiency, and we believe we'll have those specifics figured out by the end of this year. When it comes to AG-946, that drug still has a considerable distance to cover in terms of demonstrating — we're clearing its early development hurdles before we begin considering what the next stage of development is for that compound. Mitapivat today has years of efficacy and safety data, first in pyruvate kinase deficiency, now in thalassemia and sickle cell. And it keeps performing very well. So we don't need 946 in order to begin our pediatric plans, as shown by the fact that we're moving forward in pyruvate kinase deficiency.
Kelsey Goodwin
analystKelsey here, filling in for Michael. So, picking up from that previous question, maybe you could just walk us through how you expect the next-gen PKR activator to slot into your longer-term development strategy? Then regarding TIBSOVO, assuming the Phase III studies currently running read out positively, when do you figure the soonest — what's the soonest you might be able to obtain European approval for TIBSOVO?
Chris Bowden
executiveAll right. So, addressing the first one, that's 946 and the path it would take in development. That's going to hinge on what sort of data we end up seeing with mitapivat as well — since we're advancing mitapivat across all 3 indications, drawing on the activity and the safety profile we've seen so far. So as for what comes next with 946, making that determination now is premature, since we first need to understand the molecule's actual clinical attributes and whether it could deliver meaningful, substantial benefits for patients in those 3 diseases where mitapivat is currently being studied. And naturally, we keep studying and exploring conditions in which pyruvate kinase — activating pyruvate kinase might — could potentially lead to better outcomes for patients. That's an area we're actively pursuing; it's simply premature for us to say anything about how 946 would move into the next stage of development. Right now our focus is on whether we can even reach the point where that becomes possible. Then, on your TIBSOVO question: what's the soonest we might bring any of those frontline trials before the CHMP to secure approval in the frontline setting? Well, looking at AGILE, accrual needs to wrap up by the close of 2021, and from there it's an event-driven study. So we'd need a real sense of how quickly events are accumulating, when we'd unblind, and at that point we'd be off and filing. That should give you a general picture. As for HOVON, we haven't yet provided guidance on when accrual finishes, because as I mentioned, we're still opening sites in this large global trial. Our hope is that — the moment we have a positive study from these trials in hand, we'd want to bring it before the CHMP, FDA and other regulators as quickly as possible. At this stage, though, it's simply premature for us to offer specific guidance.
Kalpit Patel
analystKalpit here, filling in for Mark. I've got a few questions regarding the NIH study, particularly around the polymerization markers, p50 and t50. Do you think the changes observed so far, as shown in the ASH abstract, are clinically meaningful enough to demonstrate a long-term decrease in VOCs? Also, could you speak to how these changes stack up against what was previously observed with Oxbryta in earlier-stage trials?
Chris Bowden
executiveYes. We do believe there's — it certainly has the potential to lower VOCs, based on what our p50 and t50 assays are showing. A difficulty has been that no direct correlation exists where a certain amount of improvement corresponds to a certain amount of reduction in VOC frequency. That said — even so, from what we're observing, we think there's definitely some potential there. Certainly the early data with voxelotor, examining several important endpoints — whether that was sickling assays at specific sites, LDH, and those sorts of things — when we compare our data at a similar time point, with all the caveats that come with differing patient counts, cross-trial comparison, different time points, concomitant medications; so there are quite a few caveats attached. But we look at the overall profile we're seeing. Whether it involves the sickling assays you mentioned, whether it's LDH, specific sites, and other elements, we're very — we feel really good about what we're seeing. That's why we declared we have proof of concept. We were advancing to Phase III at the time of EHA when we reviewed the initial patient data. Another point I'll make: I think there's understandable interest in all these new drugs entering the space, and we get asked, "Well, what's the value of having mitapivat if it raises hemoglobin, since that's what voxelotor does too." There's the VOC component you ask us lots of questions about, and there's also the fact that the proportion of patients achieving a 1 gram or greater increase with voxelotor is about 50%. So a number of patients have no hemoglobin response at all; so we could see ourselves as being a very good drug for those patients, just to begin with.
Kalpit Patel
analystAll right. Then, from what I understand, the NIH study revealed a few VOCs in a small number of patients, whether while the study was running or when it wrapped up. So I suppose, could you describe those patients for us — what their baseline or historical VOC rates looked like, assuming the data is available to you?
Chris Bowden
executiveSure. Regarding how many VOCs they experienced annually and how predictable those were, we lack substantial information from before the study began. According to the investigator's overall evaluation: indeed, a single VOC occurred while a taper was underway. We adjusted the taper somewhat, and none have appeared since then. Also, there was one instance at the conclusion — as the study was ending — meaning it happened once that patient had gone without the drug for quite a while; plus multiple triggering circumstances were present in that patient's life that would have elevated their risk; so this is something we keep monitoring. Across any of the trials, VOCs come along with the development process. That's precisely why a control is essential — to truly understand what is happening with that end point — and it ranks among our major questions.
Chris Liu
analystThis is Chris, filling in for Andy. I just wanted to ask about the elevated heart rate you observed in the abstract. I'm curious how thoroughly that's been characterized — whether it involved an arrhythmia or was simply tachycardia — and whether any additional cardiac events have turned up in other trials or in preclinical work.
Chris Bowden
executiveWhat that amounts to is a heart rate exceeding 100 beats per minute without symptoms. Under the common toxicity criteria, no intervention is needed for that, since it's asymptomatic. We've found no evidence pointing to a cardiac signal tied to this drug. What happens is patients come in, they get assessed, and this shows up as part of their vital signs. There were 3 people whose heart rate went past 100, yet they were otherwise doing well and experienced no symptoms linked to it. That sums it up, and across our other studies we haven't detected any other signals hinting at a cardiac issue that should worry us. We keep monitoring safety in every sense, across the full set of trials. So far, this hasn't been anything we've needed to zero in on. And my view is that those 3 patients with an asymptomatic rate above 100 won't push us toward anything alarming or change the safety profile we've described up to now.
Chris Liu
analystUnderstood, and I have another item, if that's okay. I'm curious about the Gardos channel — the possible way it works for that other pipeline product that was aimed specifically at the Gardos channel. One of the theories put forward for why VOCs went up involved hyperviscosity. So I wanted to ask whether you have any viscosity information that might point to something else or argue against that.
Chris Bowden
executiveWell, the — I believe there's nothing particular when it comes to hyperviscosity information. Bruce Car will — I'll have him add anything more on that. But I think the piece of what we're accomplishing by reducing 2,3-DPG and talking specifically about sickling is stopping the red cell from turning sticky and misshapen; so I wouldn't expect that to be an issue, hyperviscosity if, actually, we are observing — if it ends up that we can, as time goes on, observe steady rises in MCV and gain some understanding of the — this is truly the cause; so that isn't something I'm worried about. It's notable that a portion of the information now being presented at ASH, for example, GBT's publication, where a minority of patients, a small percentage of patients had hemoglobin rises to 12 or 13 that they published, surprisingly, that those patients had the lowest frequency of VOCs and it could be that this worry, which has always existed, about how high you can get hemoglobin up. It will continue to exist, without question, among experts and clinicians who treat sickle cell disease. But perhaps now matters will become somewhat more nuanced and we'll simply need to keep tracking this breaking news and as these data evolve. Bruce, any thoughts on the Gardos channel part, please?
Bruce Car
executiveNo, I believe you pretty much hit everything, Chris — those factors that could cause hyperviscosity. You brought up, first, how sticky the red cells are; our view is that we tackle that and make it better — the overall condition of the red cell and how inclined it is toward that. A second key factor would be an extremely elevated packed — PCV, packed cell volume; that's not something we're probably going to see. And you already noted as well that within that upper range, we appear to be performing quite nicely regardless. So I don't see anything further a person could take away from a trial in which the active agent works through a mechanism of action so drastically unlike our growth. So I'd say it's likely inappropriate to extrapolate between the 2 mechanisms of action when it comes to worries about this possible side effect.
Jacqualyn Fouse
executiveThanks, operator. I want to emphasize once more that even with the difficulties and unpredictability that keep affecting the globe right now, both I and everyone at Agios stay incredibly enthusiastic about how far we've come in our key areas during this year, and we also anticipate 2021 bringing plenty of catalysts. In conclusion, my gratitude goes out to my Agios coworkers for the commitment and enthusiasm they show in striving to improve patients' lives. Additionally, I wish to express appreciation to every patient, caregiver, and physician taking part in our clinical studies. Absent their involvement, our current work would be impossible. Finally, thank you all for being with us on today's call, and we'll be in touch before long.
Operator
operatorTo all of you, that brings us to the end of today's conference call. We appreciate everyone taking part. At this point, you're welcome to hang up. Have a wonderful day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.